2024-12-22 13:50:49
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
Health/ 2023-08-16
First Patient Dosed in Pivotal Phase III...

MELBOURNE,Australia,Aug. 11,2023-- Telix Pharmaceuticals Limited (ASX: TLX,Telix,the Company)today announces that a first patient has been d...

Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China
Health/ 2023-08-16
Antengene Enters into Commercialization ...

- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China,broa...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release